The medical director of the stroke recovery program at Hackensack Meridian Health JFK Johnson Rehabilitation Institute provided clinical insights into her presentation focused on expanding rehab care for stroke survivors across settings. [WATCH TIME: 5 minutes]
At ECTRIMS 2025, the associate professor at Pontifical Catholic University of Chile discussed global challenges in diagnosing multiple sclerosis early. [WATCH TIME: 5 minutes]
At MDS 2025, the lead specialist for patient insights at Lundbeck spoke about the importance of considering patient and caregiver voices when designing clinical trials. [WATCH TIME: 3 minutes]
The chief medical officer at Dyne Therapeutics highlighted z-rostudirsen’s ability to restore dystrophin and improve function across DMD severity levels, setting the stage for a potential 2026 accelerated approval. [WATCH TIME: 4 minutes]
This segment outlines the objectives, patient population, and conduct of the phase 3 OCEANIC-STROKE trial evaluating asundexian for secondary stroke prevention.
Neurology News Network for the week ending November 15, 2025. [WATCH TIME: 4 minutes]
At ECTRIMS 2025, the staff neurologist at Cleveland Clinic’s Mellen Center for MS discussed developing a machine-learning tool to predict individualized risk of recurrent disease activity in multiple sclerosis. [WATCH TIME: 6 minutes]
At MDS 2025, the chairman and CEO at ABLi Therapeutics discussed phase 2 results of risvodetinib, a highly selective c-Abl inhibitor, in patients with Parkinson disease. [WATCH TIME: 5 minutes]
The executive vice president of public policy and advocacy at the Muscular Dystrophy Association discussed how collaboration can improve policy, funding, and care for patients with neuromuscular diseases. [WATCH TIME: 7 minutes]
Panelist discuss how chronic inflammatory demyelinating polyneuropathy (CIDP) clinical trials have progressed toward patient-focused designs that strengthen scientific rigor while safeguarding participants.
The president of the National Society of Genetic Counselors discussed the 2025 NSGC conference, highlighting AI and gene therapies as key topics, while noting the importance of genetic counselors in clinical care. [WATCH TIME: 4 minutes]
The co-founder of the Women Neurologists Group shared her experiences from the 4th Annual Women in Neurology Conference in Colorado Springs, highlighting its focus on education and wellness. [WATCH TIME: 6 minutes]
The chief medical officer at Dyne Therapeutics discussed the ACHIEVE trial’s early results, highlighting z-basivarsen’s potential to meaningfully improve muscle and CNS function in patients with myotonic dystrophy type 1. [WATCH TIME: 3 minutes]
The vice president and Asset Head of Rare and Ultra-Rare Diseases at UCB discussed the landmark FDA approval of doxecitine/doxribitine, the first-ever therapy for thymidine kinase 2 deficiency (TK2d). [WATCH TIME: 3 minutes]
The vice president of Rare Disease Strategy at Worldwide Clinical Trials discussed how genetic counselors are becoming integral to the design, execution, and interpretation of clinical research. [WATCH TIME: 3 minutes]
In this initial episode, neurologist Mike Sharma, MD, explains the biological rationale for inhibiting factor XIa and how its unique mechanism may allow stroke prevention with minimal bleeding risk.
Experts discussed the benefits and challenges of once-nightly versus twice-nightly oxybate regimens for narcolepsy, emphasizing adherence, patient lifestyle, and comorbidity considerations. [WATCH TIME: 5 minutes]
Experts discussed REFRESH study data highlighting oxybates’ tolerability, effectiveness, and potential to reduce stimulant burden in patients with narcolepsy. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending November 8, 2025. [WATCH TIME: 4 minutes]
Experts discussed the prevalence of comorbidities in narcolepsy and how targeted therapies, particularly oxybate, can improve both sleep quality and associated psychiatric symptoms. [WATCH TIME: 9 minutes]
Experts discussed findings, presented at the 2025 World Sleep Congress, showing how once-nightly oxybate improved adherence, quality of life, and partner burden in patients with narcolepsy. [WATCH TIME: 9 minutes]
Panelist discuss the clinical reasoning, electrophysiologic tools, and consensus criteria that underpin accurate diagnosis and differentiation of chronic inflammatory demyelinating polyneuropathy (CIDP) from other neuropathies.
Panelists discuss how successful myasthenia gravis management requires early diagnosis and treatment, active listening to understand individual patient needs, shared decision-making, aggressive use of targeted therapies to achieve minimal symptom expression, and comprehensive patient education to support optimal care outcomes.
The chief medical officer at Dyne Therapeutics discussed the scientific rationale and clinical progress of z-basivarsen, an antisense oligonucleotide therapy designed to correct mis-splicing in myotonic dystrophy type 1. [WATCH TIME: 5 minutes]
An investigator at Kuakini Health Systems spoke about the global importance of the Honolulu-Asia Aging Study, highlighting its history and findings, including data surrounding the diagnosis of neurodegenerative diseases. [WATCH TIME: 11 minutes]
The neuroscience program coordinator at Loyola University Medical Center talked about a recent global nurse survey for those caring for patients with generalized myasthenia gravis. [WATCH TIME: 5 minutes]
The associate professor of clinical neurology at Keck Medicine of USC discussed advancements in therapeutics, the growing focus on biomarkers, and ongoing challenges in myasthenia gravis. [WATCH TIME: 4 minutes]
The associate professor of neurology at Yale School of Medicine discussed 52-week data from the phase 3 MINT trial of inebilizumab in patients with generalized myasthenia gravis. [WATCH TIME: 5 minutes]
The head of Rare Diseases US at UCB talked about the company’s latest data on rozanolixizumab and zilucoplan in patients living with generalized myasthenia gravis. [WATCH TIME: 3 minutes]
In this final segment, Joseph Sullivan, MD, outlines the rationale, design, and key considerations behind the phase 3 EMPEROR trial, which aims to confirm zorevunersen’s efficacy and potential disease-modifying effects in Dravet syndrome. [WATCH TIME: 3 minutes]
